West Pharma Q3 net sales $874.5M, +8.7% YoY; raises FY26 sales and adjusted EPS guidance

WEST PHARMACEUTICAL SERVICES INC

Q3 net sales $874.5M, up 8.7% YoY (organic +11.9%); diluted EPS $3.02, up 57.3%; adjusted diluted EPS $2.66, up 35.7%.
FY2026 net sales guidance raised to $3.41B-$3.42B from $3.345B-$3.380B; adjusted diluted EPS raised to $9.38-$9.48 from $8.85-$9.05.
HVP Components net sales $466.7M, up 19.7% (organic +20.3%) and 53% of total; Proprietary Products segment sales $728.8M, up 12.6%.
West Vantage net sales $145.7M, down 7.3% (organic -6.6%); Standard Products $163.0M, up 2.9%; SmartDose 3.5mL sales $11.8M vs $29.8M prior-year.
Repurchased $231M stock in Q3, $685M YTD; YTD operating cash flow $403M; FY26 capex guidance cut to $215M-$220M; Q4 dividend $0.26/share, up 18%.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.